The Future of IBD Therapy: Where Are We and Where Should We Go Next?

• Published in: Digestive diseases (Basel) Vol. 34; no. 1-2; p. 175
• Main Authors: Mao, Ren, Hu, Pin-Jin
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2016
• Subjects: Biological Products - therapeutic use; Biological Therapy; Gastrointestinal Microbiome; Humans; Immunosuppressive Agents - therapeutic use; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - microbiology; Precision Medicine
• ISSN: 1421-9875
• DOI: 10.1159/000443135

The advent of biologic agents opens up a new era for the treatment of inflammatory bowel disease (IBD). In this era, the treatment goal has evolved from the traditional goal of clinical remission to a combination of clinical remission, laboratory normalization and mucosal healing, designated as 'complete deep remission'. Such complete deep remission comprises a more ambitious disease control strategy that is believed to probably modify the natural course of IBD. To achieve this goal, optimization of current strategy and introduction of novel therapies have gained significant interest. In this concise review, we aim to provide an overview of the current status and future direction of IBD treatment. Specifically, we will describe the application of personalized therapy, development of new biologics, intestinal microbiome manipulation and out-of-the-box agents for IBD. More evidence is still desirable to better optimize the current treatment and apply novel biologics. Personalized medicine has the potential to optimize efficacy, decrease the risk of adverse events and minimize costs and should be proposed as a standard of care for the management of IBD.